Global EditionASIA 中文雙語Fran?ais
    China
    Home / China / Health

    Study finds virus antibodies last at least 12 months

    By WANG XIAOYU | CHINA DAILY | Updated: 2021-07-08 09:27
    Share
    Share - WeChat
    A recovering pneumonia patient gives a thumbs-up to medical workers at Wuhan University's Zhongnan Hospital, in early 2020. [GAO XIANG/FOR CHINA DAILY]

    Antibodies against the novel coronavirus can last for at least 12 months in more than 70 percent of recovered COVID-19 patients, a study published by Chinese researchers on Tuesday shows.

    The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of SARS-CoV-2", the study said.

    The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Center for Translational Medicine at Shanghai Jiao Tong University.

    Researchers collected 1,782 convalescent plasma samples from 869 recovered COVID-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus.

    Testing results showed that in nine months, levels of the antibody dropped to 64.3 percent of the initial level when they contracted the virus, and then stabilized into the 12th month.

    "It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday.

    The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months.

    Among participants aged 18 to 55, the older ones developed higher antibody levels, it added.

    The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered COVID-19 patients.

    The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas.

    As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday.

    China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
     
    亚洲精品无码mv在线观看网站| 亚洲日本中文字幕区| 最近中文字幕mv免费高清视频8 | 精品久久久无码人妻中文字幕豆芽| 午夜福利av无码一区二区| 欧美视频中文字幕| 无码中文字幕日韩专区| 亚洲av永久无码精品漫画 | 亚洲日韩在线中文字幕综合| 人看的www视频中文字幕| 少妇精品无码一区二区三区| 中文字幕精品久久久久人妻| 亚洲中文精品久久久久久不卡| 99无码熟妇丰满人妻啪啪| 亚洲爆乳无码一区二区三区| 中文字幕国产第一页首页| 中文字幕精品一区影音先锋| 精品久久久无码人妻中文字幕| 国99精品无码一区二区三区| 无码人妻黑人中文字幕| 国产成人无码区免费网站| 日韩人妻无码一区二区三区久久99 | 中文字幕AV影片在线手机播放| 国内精品人妻无码久久久影院| 亚洲av永久无码精品漫画| 一本大道东京热无码一区| 无码人妻丝袜在线视频| 亚洲七七久久精品中文国产| 中文字幕一区视频| 最好看的中文字幕最经典的中文字幕视频| 亚洲Av无码国产情品久久| 国产精品无码久久久久| 精品无码人妻一区二区三区品| 精品人无码一区二区三区| 国产精品va无码一区二区| 国产V亚洲V天堂无码| 97免费人妻无码视频| 国产亚洲精品无码专区| 免费 无码 国产在线观看观| 亚洲一级特黄大片无码毛片 | 中文字幕在线观看有码|